Brand Name | Status | Last Update |
---|---|---|
enbrel | Biologic Licensing Application | 2023-12-06 |
Expiration | Code | ||
---|---|---|---|
etanercept, Enbrel, Immunex Corporation | |||
2106-05-27 | Orphan excl. | ||
etanercept, Enbrel Mini, Immunex Corporation | |||
2106-05-27 | Orphan excl. |
Code | Description |
---|---|
J1438 | Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 7 | 10 | 38 | 62 | 64 | 180 |
Psoriasis | D011565 | EFO_0000676 | L40 | 3 | 6 | 36 | 31 | 35 | 108 |
Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 4 | 9 | 17 | 21 | 50 |
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 6 | 8 | 16 | 30 |
Juvenile arthritis | D001171 | EFO_1002007 | M08 | 1 | 2 | 8 | 2 | 5 | 17 |
Spondylarthritis | D025241 | — | — | — | 2 | 1 | 5 | 3 | 10 |
Spondylarthropathies | D025242 | EFO_0000706 | M47 | — | 1 | 1 | 4 | 2 | 7 |
Axial spondyloarthritis | D000089183 | — | — | — | — | — | 4 | 2 | 6 |
Arthritis | D001168 | HP_0001369 | M05-M14 | — | 1 | 2 | 1 | 1 | 4 |
Rheumatic fever | D012213 | EFO_1001160 | I00-I02 | — | — | 1 | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 8 | 11 | 3 | — | — | 15 |
Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | 2 | 4 |
Neoplasms | D009369 | — | C80 | 3 | 1 | 1 | — | — | 4 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | 3 | 4 |
Uveitis | D014605 | HP_0000554 | H20.9 | — | 1 | 1 | — | 1 | 3 |
Stevens-johnson syndrome | D013262 | EFO_0004276 | L51.1 | — | — | 1 | — | 1 | 2 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | 1 | — | — | 2 |
Pneumonia | D011014 | EFO_0003106 | — | 1 | 1 | 1 | — | — | 2 |
Dermatomyositis | D003882 | EFO_0000398 | M33 | 1 | 1 | 1 | — | — | 2 |
Granulomatosis with polyangiitis | D014890 | EFO_0005297 | M31.3 | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 10 | 2 | — | — | — | 12 |
Myelodysplastic syndromes | D009190 | — | D46 | 2 | 5 | — | — | — | 5 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | 1 | — | — | 1 | 5 |
Leukemia | D007938 | — | C95 | 1 | 4 | — | — | — | 4 |
Graft vs host disease | D006086 | — | D89.81 | — | 4 | — | — | — | 4 |
Hidradenitis suppurativa | D017497 | — | L73.2 | — | 2 | — | — | 1 | 3 |
Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 1 | 3 |
Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | 2 | — | — | — | 2 |
Discoid lupus erythematosus | D008179 | — | L93.0 | — | 2 | — | — | — | 2 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | 2 | 3 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
Metabolic bone diseases | D001851 | HP_0000938 | — | 1 | — | — | — | — | 1 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | — | — | — | — | 1 |
Persian gulf syndrome | D018923 | EFO_0007430 | — | 1 | — | — | — | — | 1 |
Occupational diseases | D009784 | — | — | 1 | — | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 2 | 2 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 2 | 2 |
Papulosquamous skin diseases | D017444 | — | L40-L45 | — | — | — | — | 2 | 2 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | — | 1 | 1 |
Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 1 | 1 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 1 | 1 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 1 | 1 |
Drug common name | Etanercept |
INN | etanercept |
Description | Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.
|
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: tumor necrosis factor receptors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201572 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00005 |
UNII ID | OP401G7OJC (ChemIDplus, GSRS) |